Ziopharm Oncology (ZIOP) Misses Q3 EPS by 34c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ziopharm Oncology Reports Third Quarter 2019 Financial Results
November 7, 2019 4:05 PM ESTPhase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI)
New agreement with MD Anderson Cancer Center to expand library of T-cell receptors (TCRs) targeting neoantigens; Enables new clinical trials
Balance sheet strengthened in Q3; cash into H1 2021
 Company to host conference call and webcast today at 4:30 p.m. ET
BOSTON, Nov. 07, 2019 (GLOBE NEWSWIRE) --... More
